Voloridge Investment Management
CUE icon

Voloridge Investment Management’s Cue Biopharma CUE Stock Holding History

Voloridge Investment Management’s Portfolio CUE Stock Details CUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-456
Closed -$335K – 1290
2020
Q2 		$335K Buy
+456
New +$330K ﹤0.01% 1113

Other funds holding CUE

NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
SPC
Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return
CA
Corriente Advisors Fort Worth, Texas $9.53M AUM 805.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
RSWM
Robertson Stephens Wealth Management San Francisco, California $3.57B AUM 28.36% 1-Year Est. Return

Voloridge Investment Management's CUE Position: Q3 2020 in Review

Voloridge Investment Management sold out of Cue Biopharma (CUE) in Q3 2020, closing a stake of 456 shares — an estimated $335K sold.

Voloridge Investment Management first reported a position in CUE in Q2 2020 and held it in 1 quarter. The position peaked at $335K in Q2 2020. 92 funds tracked by Wall St. Rank hold CUE as of Q3 2020.

  • Voloridge Investment Management reported no remaining Cue Biopharma position as of Q3 2020 after selling out during the quarter.
  • Voloridge Investment Management sold 456 Cue Biopharma shares in Q3 2020, an estimated $335K.
  • Voloridge Investment Management first reported a position in Cue Biopharma in Q2 2020 and held it in 1 quarter.
  • Voloridge Investment Management's Cue Biopharma position peaked at $335K in Q2 2020.
  • 92 funds tracked by Wall St. Rank held Cue Biopharma as of Q3 2020.

Based on Voloridge Investment Management's 13F filing for Q3 2020, filed 16 Nov 2020.